Access to allogeneic hematopoietic SCT for patients with MDS or relapsed AML treated according to protocols of the Dutch Childhood Oncology Group

作者：Joris M M^*; Bierings M B; Egeler R M; Claas F H J; van Rood J J; Oudshoorn M

来源：Bone Marrow Transplantation, 2012, 47(5): 677-683.

DOI：10.1038/bmt.2011.168

• allogeneic
• hematopoietic SCT
• access

To investigate whether all patients in need of an allogeneic hematopoietic SCT (HSCT) are offered one, we retrospectively investigated the policy for all children diagnosed with myelodysplastic syndrome (n = 90) or relapsed AML (n = 75) between 1998 and 2008. These children are registered at diagnosis and treated according to protocols of the Dutch Childhood Oncology Group, which provides accurate disease incidence data and protocol-indicated appropriateness for HSCT. For 48 (30%) patients, a family donor was identified; for 90 (57%) patients, an unrelated donor (UD) search was performed; and for 21 (13%) patients, no UD search was initiated. Reasons for not initiating an UD search include: progressive disease (n = 10), conserve quality of life (n = 1), stable disease (n = 3), immunosuppressive therapy (n = 2), patient death (n = 3), patient lives abroad (n = 1) and second relapse (n = 1). On the basis of the time interval between date of diagnosis and date of death/last follow-up, for eight (5%) patients, it may be questioned why an UD search was not performed. The fact that 95% of all children are given the option of an allogeneic HSCT is encouraging and reasons not to transplant seem fair in most cases. Bone Marrow Transplantation (2012) 47, 677-683; doi:10.1038/bmt.2011.168; published online 22 August 2011

• 出版日期2012-5